What is the recommended approach to diagnose and manage anemia in a patient with chronic kidney disease?

Anemia in CKD: Diagnosis and Management

Diagnose anemia in CKD by checking hemoglobin levels and iron parameters (ferritin, TSAT, and ideally reticulocyte hemoglobin content or % hypochromic RBCs), then treat with iron supplementation first—using IV iron for hemodialysis patients and either oral or IV iron for non-dialysis patients—before considering erythropoiesis-stimulating agents (ESAs) to target hemoglobin levels of 10-12 g/dL, avoiding levels above 13 g/dL due to increased cardiovascular risk and mortality. 1, 2

Diagnostic Approach

Initial Screening

• Screen all CKD patients for anemia during initial evaluation 3
• Check hemoglobin, ferritin, and transferrin saturation (TSAT)
• Do not rely on ferritin or TSAT alone for iron deficiency diagnosis 1, 4

Defining Iron Deficiency

Absolute Iron Deficiency:

• Non-dialysis/peritoneal dialysis: TSAT ≤20% AND ferritin ≤100 ng/mL
• Hemodialysis: TSAT ≤20% AND ferritin ≤200 ng/mL 1, 3

Functional Iron Deficiency:

• TSAT ≤20% with ferritin >100 ng/mL (non-dialysis) or >200 ng/mL (hemodialysis)
• Represents inadequate iron availability despite adequate stores, often due to inflammation-induced hepcidin elevation 1

Advanced Diagnostic Parameters

When available, use reticulocyte hemoglobin content (RetHb) or % hypochromic RBCs rather than ferritin alone—these better predict responsiveness to IV iron 1, 4. The NICE guideline found that % hypochromic RBCs >6% was the most cost-effective diagnostic strategy 4.

Management Algorithm

Step 1: Iron Repletion (First-Line Therapy)

For Hemodialysis Patients:

• Use IV iron as preferred route 1, 2
• High-dose, low-frequency administration is recommended for adults
• Low-dose, high-frequency may be more appropriate for children and some in-center hemodialysis patients 4
• Proactive IV iron strategy reduces ESA requirements 1

For Non-Dialysis CKD Patients:

• Trial of oral iron first if not receiving ESAs 4
• Consider IV iron if oral iron fails, not tolerated, or patient is receiving ESAs 1, 2
• Newer oral formulations (ferric citrate) may improve iron utilization 1

Critical Pitfall: The 2021 KDIGO conference highlights ongoing uncertainty about optimal ferritin targets, with trials needed to compare holding iron at ferritin levels of 400 vs 700 vs 1200 ng/mL in hemodialysis patients 1. Current practice varies, with US providers often accepting higher ferritin levels than international guidelines 5.

Step 2: Erythropoiesis-Stimulating Agents (ESAs)

Indications:

• Iron-replete patients with persistent anemia
• Target hemoglobin: 10-12 g/dL 6, 2

Critical Safety Concern:

• Never target hemoglobin ≥13 g/dL—associated with increased mortality and major adverse cardiovascular events 6
• Hemoglobin levels of 11.5-13 g/dL show no evidence of benefit over lower levels 6

ESA Resistance Evaluation: If inadequate response despite adequate dosing, systematically evaluate:

1. Infection/inflammation (most common)—check C-reactive protein 7
2. Occult blood loss—suspect if increasing ESA doses needed or falling hemoglobin 7
3. Secondary hyperparathyroidism (osteitis fibrosa)—check intact PTH 7
4. Aluminum toxicity (less common now) 7
5. Hemoglobinopathies (thalassemia, sickle cell disease) 7
6. Folate or B12 deficiency 7

Step 3: Novel Therapies - HIF-Prolyl Hydroxylase Inhibitors (HIF-PHIs)

Current Status:

• Oral agents that stimulate endogenous erythropoietin production 8
• May improve iron utilization, particularly with oral iron 8
• ESAs remain preferred first-line therapy due to greater clinical experience and safety data 5

Potential Advantages:

• Oral dosing convenience
• May be more effective in chronic inflammatory states (CRP >5 mg/L) 8

Concerns Requiring Further Study:

• Risk of tumor growth enhancement
• Worsening diabetic retinopathy
• Cyst growth in autosomal dominant polycystic kidney disease
• Less clinical experience with long-term safety 1, 8

US-Specific Context: Only one HIF-PHI is FDA-approved, restricted to dialysis patients receiving treatment ≥3 months 5

Key Pathophysiology Considerations

The anemia of CKD results from multiple mechanisms 1:

• Inadequate erythropoietin production (primary cause)
• Disordered iron homeostasis via hepcidin elevation
• Chronic inflammation
• Shortened RBC survival
• Uremic toxin-mediated bone marrow suppression

Hepcidin is the master regulator—elevated in CKD due to inflammation and reduced renal clearance, it blocks iron absorption and release from stores 1. This explains why functional iron deficiency is common despite adequate ferritin levels.

Monitoring Strategy

• Hemoglobin: Monthly initially, then every 3 months when stable
• Iron parameters: Every 3 months for non-dialysis patients; monthly for hemodialysis patients receiving IV iron
• Avoid over-reliance on ferritin alone—incorporate TSAT and RBC parameters when available 1

Red Blood Cell Transfusions

Reserve for:

• Acute symptomatic anemia
• Hemodynamic instability
• Failure of medical management
• Avoid routine transfusions due to iron overload risk, allosensitization (problematic for transplant candidates), and infection risk 1, 2

Common Pitfalls to Avoid

1. Targeting hemoglobin >13 g/dL—increases mortality 6
2. Diagnosing iron deficiency with ferritin alone—misses functional deficiency 1, 4
3. Starting ESAs before iron repletion—reduces efficacy and increases ESA requirements 1
4. Ignoring inflammation as cause of ESA resistance—check CRP 7
5. Overlooking occult GI blood loss—common in CKD patients on anticoagulation 7